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Chronic obstructive pulmonary disease (COPD) represents a significant cause of global morbidity and mortality, with a
substantial economic impact. Recent changes in the Global initiative for chronic Obstructive Lung Disease (GOLD)
guidance refined the classification of patients for treatment using a combination of spirometry, assessment of
symptoms, and/or frequency of exacerbations. The aim of treatment remains to reduce existing symptoms while
decreasing the risk of future adverse health events. Long-acting bronchodilators are the mainstay of therapy due to
their proven efficacy. GOLD guidelines recommend combining long-acting bronchodilators with differing mechanisms
of action if the control of COPD is insufficient with monotherapy, and recent years have seen growing interest in the
additional benefits that combination of long-acting muscarinic antagonists (LAMAs), typified by tiotropium, with
long-acting β2-agonists (LABAs), such as formoterol and salmeterol. Most studies have examined free combinations of
currently available LAMAs and LABAs, broadly showing a benefit in terms of lung function and other patient-reported
outcomes, although evidence is limited at present. Several once- or twice-daily fixed-dose LAMA/LABA combinations
are under development, most involving newly developed monotherapy components. This review outlines the existing
data for LAMA/LABA combinations in the treatment of COPD, summarizes the ongoing trials, and considers the
evidence required to inform the role of LAMA/LABA combinations in treatment of this disease.
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Currently the fourth leading cause of death globally [1],
chronic obstructive pulmonary disease (COPD) is a major
cause of morbidity and mortality, projected to become the
world’s third leading cause of mortality by 2020 [2]. Char-
acterized by progressive airflow limitation, COPD also has
a major economic impact, contributing to US$53.7 billion
in related direct costs in 2008 in the US [3].
As an area of interest for physicians, and a logical pro-
gression from monotherapy for those seeking to further
improve outcomes in patients with respiratory disease,
the subject of combined bronchodilation with broncho-
dilators of differing modes of action has been discussed
in the literature previously [4-8]. The aim of this review
is to focus more specifically on the combination of long-* Correspondence: DTashkin@mednet.ucla.edu
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distribution, and reproduction in any mediumacting muscarinic antagonists (LAMAs) and long-acting
β2-agonists (LABAs) for the treatment of COPD, sum-
marizing data from recent peer-reviewed publications
and published abstracts.
Evolving COPD guidelines
2011 saw a substantial revision of the Global initiative
for chronic Obstructive Lung Disease (GOLD) guidelines
for diagnosis, management, and prevention of COPD,
which has recently been updated [9]. Recommendations
for treatment are no longer based primarily on categori-
zation (“staging”) by spirometric assessment, but on
categorization by existing symptoms (using validated
modified Medical Research Council and COPD Assess-
ment Test questionnaires) and risk (based on severity of
airflow limitation and history of exacerbations). This ap-
proach acknowledges the importance of consideration of
both short- and long-term outcomes when making treat-
ment decisions (Figure 1) [9].d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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Figure 1 Model of symptom/risk of evaluation of COPD [9]. From the Global Strategy for Diagnosis, Management and Prevention of COPD
2013, Global initiative for chronic Obstructive Lung Disease (GOLD), http://www.goldcopd.org. COPD = chronic obstructive lung disease;
GOLD = Global initiative for chronic Obstructive Lung Disease; mMRC =modified Medical Research Council; CAT = COPD Assessment Test.
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COPD maintenance therapy
Two key classes of bronchodilators have been developed
in COPD: β2-agonists and muscarinic antagonists. Short-
acting bronchodilators, such as ipratropium, albuterol,
and metaproterenol, have formed the cornerstone of initial
COPD therapy for the past two decades [9,10]. Subse-
quently, long-acting bronchodilators were developed. The
twice-daily LABAs salmeterol and formoterol first became
available for maintenance therapy of COPD more than
15 years ago, while the once-daily LAMA tiotropium has
been available for 10 years and is the most widely pre-
scribed maintenance monotherapy bronchodilator in
COPD [11]. Inhaled bronchodilators, as monotherapy or
in combination, remain the mainstay for patients in all
categories (Table 1) [9]. Long-acting bronchodilators, such
as tiotropium, formoterol, and salmeterol, are proven to
provide long-term improvements in lung function, quality
of life, and exacerbations in patients with COPD [12-14].
Long-acting bronchodilators (e.g., tiotropium, salmeterol)
also reduce lung hyperinflation and dyspnea, and increase
exercise endurance [15,16], although a recent review sug-
gested further data are required on the benefits of long-
acting bronchodilators on exercise tolerance [17]. There
are a variety of long-acting bronchodilators available
(Table 2) [18-34]. The once-daily LABA indacaterol, theonce-daily LAMA glycopyrronium, and twice-daily LAMA
aclidinium represent newer, recently licensed therapies,
and there are also several once-daily LABAs and LAMAs
in development, including olodaterol, vilanterol, and
glycopyrrolate (Table 2).
Combination bronchodilation: rationale
Guidelines recommend combination therapy involving
two long-acting bronchodilators with differing modes of
action in patients whose COPD is not sufficiently con-
trolled with monotherapy (Table 1) [9]. The mechanistic
rationale for combination of a muscarinic antagonist and a
β2-agonist has been reviewed in detail recently [35,36]; as
such, we will only briefly discuss it here. Airway smooth
muscle relaxation (leading to bronchodilation) can be
achieved via two main routes: inhibition of acetylcholine
signaling via muscarinic M3 receptors on airway smooth
muscle with a muscarinic antagonist, or stimulation of
β2-adrenoceptors with a β2-agonist [35,36]. Targeting
these two mechanisms of bronchoconstriction, theoretic-
ally, has the potential to maximize the bronchodilator re-
sponse without increasing the dose of either component,
and helps to overcome the inter- and intra-patient vari-
ability in response to individual agents seen in COPD [35].
The interaction between the two systems has yet to be
fully elucidated; however, β2-agonists can amplify the
Table 1 GOLD guidelines (2013): pharmacologic therapies for stable COPDa [9]
Patient group 1st choice 2nd choice Alternative
A: GOLD 1-2 Short-acting anticholinergic
prn OR SABA prn
LAMA OR LABA OR SABA and
short-acting anticholinergic
Theophylline
Low risk of exacerbation, less symptoms
B: GOLD 1-2 LAMA OR LABA LAMA and LABA SABA and/or short-acting
anticholinergic
Low risk of exacerbation, more symptoms Theophylline
C: GOLD 3-4 ICS + LABA OR LAMA LAMA and LABA OR LAMA and PDE-4 inhibitor
OR LABA and PDE-4 inhibitor
SABA and/or short-acting
anticholinergic
High risk of exacerbation, less symptoms Theophylline
D: GOLD 3-4 ICS + LABA and/or LAMA ICS and LABA and LAMA
OR ICS + LABA and PDE-4 inhibitor
OR LAMA and LABA
OR LAMA and PDE-4 inhibitor
Carbocysteine
High risk of exacerbation, more symptoms SABA and/or short-acting
anticholinergic
Theophylline
From the Global Strategy for Diagnosis, Management and Prevention of COPD 2013, Global initiative for chronic Obstructive Lung Disease (GOLD),
http://www.goldcopd.org.
aMedications in each box are mentioned in alphabetical order, and, therefore, not necessarily in order of preference.
prn = as needed; SABA = short-acting β2-agonist; LABA = long-acting β2-agonist, LAMA = laong-acting muscrannic antagonist; ICS = inhaled corticosteroid;
PDE = phosphodiesterase.
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the muscarinic antagonist by decreasing the release of
acetylcholine via modulation of cholinergic neurotrans-
mission. Additionally, muscarinic antagonists have been
demonstrated to augment β2-agonist-stimulated broncho-
dilation by reducing the bronchoconstrictor effects of
acetylcholine in preclinical models [35].
The rationale for improved bronchodilation has been
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potentiates the effects of glycopyrronium to inhibit
metacholine-induced contraction of airway smooth muscle
in vitro [39]. However, specifically designed clinical studies
are required to assess whether such synergistic effects can
be observed with therapeutic doses in humans.
Combination bronchodilation: existing evidence
and ongoing studies
Short-acting muscarinic antagonist plus short-acting
β2-agonist
The concept of adding a muscarinic antagonist to a β2-
agonist is by no means new. A fixed-dose combination
(FDC) of the short-acting agents ipratropium and albuterol
(Combivent®) and of fenoterol and ipratropium (Berodual®)
clearly provides benefits over monotherapy with either
component [40-42]. Additionally, dual bronchodilation
with ipratropium and albuterol resulted in a consistently
longer response and more patients achieved a pre-specified
response level (12-15%) in forced expiratory volume in
1 second (FEV1) with the combination versus individual
components (p < 0.05) [40,41,43-45], with an equivalent or
improved safety profile.
Free combinations of LAMA plus LABA
Relatively few studies have examined the combination of
LAMAs and LABAs. Until recently, research focused on
free combinations of existing therapies, and has demon-
strated benefits on lung function and other outcomes
(Table 3) [46-69].
Following proof of concept in terms of a benefit on
FEV1 and in patients with acute exacerbations [70-72],
several randomized controlled trials have reported im-
proved lung function for tiotropium plus formoterol ver-
sus tiotropium alone [54-56,60,65,73]. Some trials have
also identified significant improvements in symptom
scores [55,56,60] and reductions in rescue medication
use [47,49,55,56,65]. A recent meta-analysis confirmed
the benefits of tiotropium plus formoterol on average
FEV1, trough FEV1, and Transition Dyspnea Index (TDI)
[74] (Table 3), with initial reports also suggesting that
the combination may provide statistically significant im-
provements in effort-induced dynamic hyperinflation
and exercise tolerance [75].
Currently available data on tiotropium plus salmeterol
are conflicting. Initial investigations indicated the
benefits of tiotropium plus salmeterol versus either
monotherapy alone, while suggesting co-administration
of once-daily salmeterol plus tiotropium was inadvisable,
due to the shorter duration of bronchodilation provided
by salmeterol [76]. The Canadian Optimal Therapy of
COPD trial investigated the impact of tiotropium plus
placebo, tiotropium plus salmeterol, or tiotropium
plus salmeterol/fluticasone on clinical outcomes in449 patients with moderate to severe COPD [48].
Tiotropium plus salmeterol/fluticasone (but not
tiotropium plus salmeterol) statistically improved lung
function and quality of life, and, while no improvement
in overall exacerbation rate was seen, reduced the num-
ber of hospitalizations for exacerbations compared to
tiotropium plus placebo [48] (Table 3). A more recent
study, however, demonstrated significant improvements
in FEV1 with salmeterol once or twice daily plus
tiotropium [59], and the combination was also associ-
ated with clinically significant improvements in TDI
(Table 3). These inconclusive data suggest that further
research is necessary to determine any advantage of
salmeterol plus tiotropium. Initial investigation of other
free combinations has also been reported (Table 3);
tiotropium plus indacaterol has been demonstrated to
improve lung function and inspiratory capacity, as well
as providing a further reduction in use of rescue medica-
tion [50]. The LAMA GSK233705 twice daily plus
salmeterol has also demonstrated significantly improved
trough FEV1 from baseline compared to monotherapy
[61]. Overall, these data broadly confirm that combin-
ation therapy has the potential to improve outcomes ver-
sus monotherapy and justify further research in this
area.
Fixed-dose combinations (FDCs)
FDCs of LAMAs and LABAs offer the potential of im-
proved convenience and compliance over use of separate
inhalers, and, during their development, the dose of each
agent to be used in combination can be optimized.
A major challenge associated with development of an
FDC is provision of improved bronchodilation over
monotherapy components while balancing the associated
adverse effects [77]. Dose-finding studies are required to
establish minimal effective doses for each agent in the
combination, as it cannot be assumed that these doses
are the same as would be used in monotherapy. Regula-
tory bodies also require investigation into any pharma-
codynamic or pharmacokinetic interactions that may
occur between the constituents, along with evidence of
the safety profile for the combination [77,78].
A number of FDCs are in development, with substantial
clinical programs (Table 4), and some Phase II/III results
are available (Table 3). In all cases, there is evidence
of improved lung function parameters with the combi-
nations versus monotherapy components. Glycopyrrolate/
glycopyrronium is being developed as part of two combina-
tions: the former plus formoterol as a twice-daily combin-
ation (Pearl Therapeutics) and the latter plus indacaterol as
a once-daily combination (Novartis). Glycopyrrolate plus
formoterol has recently reported improvements in FEV1
area under the curve from 0–12 hours (AUC0-12) versus
monotherapy with glycopyrrolate, formoterol, or tiotropium
Table 3 LABA and LAMA combinations: current evidence
Combination (manufacturer) Reference Reported results
Free combinations
GSK233705: 20 or 50 μg BID; salmeterol: 50 μg BID Beier et al. [61] Larger mean increases from baseline trough FEV1 vs placebo
with 20 μg GSK233705 + salmeterol (203 mL) and 50 μg
GSK233705 + salmeterol (215 mL) vs monotherapy with
tiotropium (101 mL) or salmeterol (118 mL)
Tiotropium: 18 μg QD; arformoterol: 15 μg BID Tashkin et al. [60] Greater improvement in FEV1 AUC0-24 from baseline with
combination (0.22 L) vs monotherapy with either arformoterol
(0.10 L) or tiotropium (0.08 L); p < 0.001
Greater improvement in TDI with combination (3.1) vs
monotherapy with either arformoterol (2.3; CI 0.03, 1.70) or
tiotropium (1.8; CI 0.50, 2.20)
Tiotropium: 18 μg QD; formoterol: 20 μg BID Hanania et al. [65] FEV1 AUC0-3 greater with combination (1.57 L) vs tiotropium
alone (1.38 L); p < 0.0001
Reduced use of rescue medication vs tiotropium alone;
p < 0.05
Tiotropium: 18 μg QD; formoterol: 20 μg BID Tashkin et al. [56] Greater FEV1 AUC0-3 with combination (1.52 L) vs tiotropium
alone (1.34 L); p < 0.0001
Greater improvement in TDI with combination than
tiotropium alone (2.30 vs 0.16; mean difference of 1.80);
95% CI 0.86, 2.74, p < 0.0002
Tiotropium: 18 μg QD; formoterol: 12 μg BID Tashkin et al. [55] Greater improvement in FEV1 AUC0-4 from baseline with
combination (0.34 L) vs tiotropium alone (0.17 L); p < 0.001
Dyspnea significantly improved with combination at week 8
(1.86) vs tiotropium alone (1.01); p = 0.013
Reduced use of rescue medication vs tiotropium alone;
p < 0.04
Tiotropium: 18 μg QD; formoterol: 12 μg QD or BID Terzano et al. [66] Greater improvement in FEV1 with combination vs tiotropium
alone at day 30 (0.16 L); p = 0.0001
Improvement in dyspnea with combinations (2.32-2.61) vs
tiotropium alone (1.0); p < 0.05
Lower rescue medication use with combinations (0.71-0.80
puffs/day) vs tiotropium alone (2.14 puffs/day); p < 0.05
Tiotropium: 18 μg QD; formoterol: 12 μg QD or BID van Noord et al. [47] Greater average improvement in FEV1 AUC0-24 0.16-0.20 L
with combinations vs 0.08 L with tiotropium alone; p < 0.05
Lower rescue medication use with combinations vs
tiotropium alone; p < 0.01 (daily rescue medication use with
tiotropium+ formoterol QD or BID) and p < 0.05 (tiotropium+
formoterol BID)
Tiotropium: 18 μg QD; formoterol: 12 μg QD or BID van Noord et al. [49] Average improvement in daytime (0.234 L) and night-time
FEV1 (0.086 L) with combination vs monotherapy with
tiotropium (p ≤ 0.001) or formoterol (p ≤ 0.01)
Lower rescue medication use with combination (1.81 puffs/day) vs
monotherapies (2.37-2.41 puffs/day); p < 0.01
Tiotropium: 18 μg QD; formoterol: 10 μg BID Vogelmeier et al. [54] Improvement in FEV1 2 h post-dose after 24 weeks with
combination vs formoterol alone (p = 0.044)
Tiotropium: 18 μg QD; indacaterol: 150 μg QD Mahler et al. [50] Greater increase in trough FEV1 from baseline with
combination: 70–80 mL difference vs tiotropium alone
(p < 0.001)
Improved trough IC with combination vs tiotropium alone:
100–130 mL; p < 0.01
Less use of albuterol as rescue medication with combination:
reduction of 0.8–1.3 puffs/day from baseline vs tiotropium
alone
Tiotropium: 18 μg QD; salmeterol: 50 μg BID Aaron et al. [48] No statistical improvement in lung function or hospitalization
rates with combination compared to tiotropium
monotherapy
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Table 3 LABA and LAMA combinations: current evidence (Continued)
Tiotropium: 18 μg QD; salmeterol: 50 μg BID van Noord et al. [59] Improved average FEV1 (0–24 h) with combination (0.142 L)
vs monotherapy with either tiotropium (0.07 L) or salmeterol
(0.045 L); p < 0.0001
Combination associated with clinically relevant improvements
in TDI focal score (p < 0.001)
Fixed-dose combinations
Glycopyrrolate: 36 and 72 μg BID; formoterol:
9.6 μg BID (Pearl Therapeutics)
Reisner et al. [53] Increase in FEV1 AUC0–12 on day 7 with combination
compared to monotherapy with either of the components,
tiotropium, and placebo (p < 0.0001)
Glycopyrrolate: 36 and 72 μg BID; formoterol:
9.6 μg BID (Pearl Therapeutics)
Reisner et al. [52] Higher morning pre-trough and peak IC with combination vs
placebo (p < 0.0005 and p < 0.005, respectively) or tiotropium
monotherapy (p < 0.05 for all comparisons)
Glycopyrrolate: 36 and 72 μg BID; formoterol:
9.6 μg BID (Pearl Therapeutics)
Reisner et al. [62] Similar metabolic and cardiac safety profile to tiotropium
Glycopyrronium: 50 μg QD; indacaterol:
300 μg QD (Novartis)
van Noord et al. [58] Improved trough FEV1 with combination: 0.226 L difference in
trough FEV1 vs placebo (p < 0.001)
Greater peak FEV1 with combination (1.709 L) vs 300 μg
indacaterol (1.579 L) and 600 μg indacaterol (1.573 L);
p < 0.0001 for both comparisons
Glycopyrronium: 100 μg QD; indacaterol:
600 μg QD (Novartis)
Van de Maele et al. [57] Increased trough FEV1 with combination (1.61 L) vs
indacaterol monotherapy 300 μg (1.46 L); p < 0.05
Glycopyrronium: 50 μg QD; indacaterol:
110 μg QD (Novartis)
Bateman et al. [68] Improved trough FEV1 with combination vs placebo (0.20 L
mean difference), indacaterol (0.07 L), glycopyrronium (0.09 L),
and tiotropium (0.08 L) monotherapy; p < 0.001
Improved TDI score with combination vs placebo (mean
difference 1.09); p < 0.001 and tiotropium (0.51 mean
difference); p < 0.05
Improved SGRQ score with combination vs tiotropium (−2.13
mean difference); p < 0.05
Reduced use of rescue medication with combination vs
monotherapies (−0.30 to −0.54 mean difference); p < 0.05
Glycopyrronium: 50 μg QD; indacaterol:
110 μg QD (Novartis)
Vogelmeier et al. [69] Improvement in trough FEV1 with combination vs salmeterol/
fluticasone (mean difference 0.103 L); p < 0.0001
Improvements in TDI score with combination vs salmeterol/
fluticasone (mean difference 0.76); p = 0.003
Lower use of rescue medication with combination vs
salmeterol/fluticasone (−0.39 puffs/day); p = 0.019)
Glycopyrronium: 50 μg QD; indacaterol:
110 μg QD (Novartis)
Dahl et al. [67] Combination increased FEV1 and FVC vs placebo over a
52-week period; p < 0.001
Tiotropium: 5 μg QD; olodaterol: 2, 5, and 10 μg
QD (Boehringer Ingelheim)
Maltais et al. [51] Higher peak FEV1 for all doses of combination investigated vs
tiotropium alone (p ≤ 0.05); higher trough FEV1 response with
tiotropium + olodaterol 5/10 μg vs tiotropium alone
(p = 0.034)
Tiotropium: 1.25, 2.5, and 5 μg QD; olodaterol:
5 and 10 μg QD (Boehringer Ingelheim)
Aalbers et al. [64] Significant improvements in FEV1 for all doses of combination
vs olodaterol alone, with evidence of a dose-dependent
response
Umeclidinium (GSK573719): 500 μg QD; vilanterol:
25 μg QD (GSK)
Feldman et al. [63] Adverse-event rate of 26%, with no single adverse event
reported in >1 patient
Combination similar to placebo in terms of cardiac
parameters
Greater change from baseline in trough FEV1 and FEV1 from
0–6 h post-dose with combination vs placebo
PubMed and relevant respiratory congresses were searched for abstracts relating to LAMA/LABA combination therapies.
BID = twice a day; FEV1 = forced expiratory volume in 1 second; QD = once a day; AUC = area under the curve; TDI = Transition Dyspnea Index; CI = confidence
interval; IC = inspiratory capacity; SGRQ = St George’s Respiratory Questionnaire.
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Table 4 LABA and LAMA combinations under investigation: ongoing trials
LAMA LABA Trial numbers Summary of ongoing Phase II/III studies
Aclidinium Formoterol NCT01572792, NCT0143797,
NCT01462942, NCT01437540,
NCT01049360
4 Phase III studies and 1 Phase II study, examining the long-term
efficacy and safety of 2 different doses of aclidinium + formoterol vs
monotherapy with either component and placebo
Glycopyrrolate Formoterol NCT01587079, NCT01587079 2 Phase II studies (both recently completed), examining efficacy of the
combination vs the monotherapy components and tiotropium
Glycopyrronium Indacaterol NCT01120691 (SPARK), NCT01202188
(GLEAM) (pivotal studies, both completed),
NCT0171251, NCT01604278, NCT01727141,
NCT01529632, NCT01709903
2 recently completed pivotal Phase III studies investigating efficacy and
safety, exacerbations, exercise, and TDI, and 5 ongoing Phase III studies,
examining safety and efficacy of combination vs placebo, monotherapy
components, and salmeterol/fluticasone
Tiotropium Olodaterol NCT01431274, NCT01431287 (pivotal studies),
NCT01525615, NCT01533922, NCT01533935,
NCT01559116, NCT01536262
7 Phase III studies, investigating efficacy and safety of combination vs
monotherapy components and effects on exercise
Umeclidinium
(GSK573719)
Vilanterol NCT01313637, NCT01316900, NCT01316913,
NCT01313650 (pivotal studies, recently
completed), NCT01716520, NCT01491802
6 Phase III studies (4 recently completed, 2 ongoing), focused primarily
on efficacy, with other studies examining AE incidence, exercise
endurance time, and exertional dyspnea
ClinicalTrials.gov was searched for Phase II and III trials of fixed-dose combinations of LAMA + LABA. Access date: 12/05/12.
LABA = long-acting β2-agonist; LAMA = long-acting muscarinic antagonist; AE = adverse event; TDI = Transition Dyspnea Index; FDA = Food and
Drug Administration.
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therapy [53] (Table 3). Indacaterol is approved at doses of
150 and 300 μg in the EU, and 75 μg in the US [79].
Early studies investigated high doses of indacaterol in
combination with glycopyrronium [57,58], but the re-
cent SHINE, ILLUMINATE, and ENLIGHTEN studies
have examined the effects of indacaterol (110 μg) plus
glycopyrronium (50 μg) (Table 3). The SHINE study
reported significantly greater improvements in trough
FEV1 after 26 weeks’ treatment with the combination
compared to monotherapy with indacaterol (mean dif-
ference 70 mL), glycopyrronium (90 mL), or tiotropium
(80 mL) [68]. This study also demonstrated improvements
in dyspnea (versus placebo and tiotropium), St George’s
Respiratory Questionnaire (versus placebo), and re-
duced use of rescue medication (versus placebo and all
monotherapies). The ILLUMINATE study has provided
interesting information on the relative effects on lung
function of a LABA/LAMA combination versus LABA/
inhaled corticosteroids (ICS): significant, sustained, and
clinically meaningful improvements in trough FEV1,
peak FEV1, and FEV1 AUC0-12 with indacaterol plus
glycopyrronium versus the LABA/ICS salmeterol/fluticasone
(p < 0.001 for all comparisons) [69]. Mean treatment
difference for indacaterol plus glycopyrronium versus
salmeterol/fluticasone ranged from 103 mL (trough FEV1)
to 155 mL (peak FEV1) [69]. Additionally, the longer-term
ENLIGHTEN study reported significant improvements in
lung function with the combination versus placebo sustained
for 52 weeks, with no evidence of tachyphylaxis [67].
Clinical Phase II trials have investigated the optimal
dosing for olodaterol added to a fixed dose of tiotropium
[51] and for tiotropium added to a fixed dose of
olodaterol [64]. Significant improvements in peak FEV1were demonstrated with tiotropium/olodaterol 5/2 μg
(p = 0.008), 5/5 μg (p = 0.012), and 5/10 μg (p < 0.0001)
versus tiotropium monotherapy [51]. Significant im-
provements were also seen in trough FEV1 with
tiotropium/olodaterol 5/10 μg versus tiotropium mono-
therapy (p = 0.034) [51], and with all doses of the com-
bination tested versus olodaterol monotherapy, with
evidence of dose ordering [64] (Table 3).
There is little information available from studies of
aclidinium plus formoterol; only initial results of preclin-
ical cardiac safety in beagle dogs have been reported [80].
Of the LAMA/LABA FDCs currently under investiga-
tion, tiotropium plus olodaterol, umeclidinium plus
vilanterol, aclidinium plus formoterol, and glycopyrronium
plus indacaterol have the largest Phase III programs, focus-
ing on efficacy, safety, exacerbations, exercise, and dyspnea
(Table 4). The development program for umeclidinium
plus vilanterol involves four large pivotal trials, one large
safety study, and two studies assessing exercise endurance,
with two ongoing trials investigating lung function and effi-
cacy. Phase III studies of glycopyrronium plus indacaterol
will compare the combination with a range of comparators,
including fluticasone/salmeterol combination and tiotro-
pium, across a variety of end points (FEV1, exacerbations,
TDI, and safety). The tiotropium plus olodaterol develop-
ment program includes two main registration trials, three
examining exercise and functional capacity, one examining
long-term safety, and a comprehensive lung function trial.
Several of the LAMA/LABA FDCs in development will
be delivered once daily (such as umeclidinium plus
vilanterol and tiotropium plus olodaterol) while others will
have twice-daily dosing (e.g., aclidinium plus formoterol).
This diversity has the potential to increase the persona-
lization of medication to individual needs; for instance,
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patients suffer from night-time symptoms [81], while
once-daily combinations may be prescribed to improve
adherence [82].
Delivery devices
Inhalation devices are intrinsically linked to the medica-
tion they deliver. As such, careful consideration of the
most appropriate delivery device is crucial to optimal
COPD therapy, along with adequate training and obser-
vation of patient technique.
The new devices currently in development for delivery
of combination inhaled LAMA/LABAs for COPD fall
into three main classes: pressurized metered dose in-
halers (pMDIs), dry powder inhalers (DPIs), and a
propellant-free Soft Mist™ Inhaler (SMI), each with its
own advantages and disadvantages (Table 5) [83-93].
Poor inhaler technique is often a main cause of sub-
optimal COPD management [83]; determining a suitable
delivery device that each individual patient will be able
to use can help to ensure adequate disease management.
For instance, a spacer or holding chamber can be used
to improve drug delivery via pMDIs in patients with
poor coordination between actuation and inhalation.
DPIs were designed to ease operation compared to
pMDIs [94]. However, it remains important to provide





pMDI Drug is dissolved in propellant
(generally HFA). When activated,
a valve system releases a metered
volume of propellant containing
the medication
Can be more cost-effect
than DPIs [84]
High fine-particle fractio




DPI Drug is delivered in powder form
on inspiration by the patient;
de-aggregation of the powder and
generation of the aerosol provided




have an accurate inhale
with DPIs without teach
Soft Mist™
Inhaler
Delivers a metered dose of medication
as a slow-moving “soft mist” through
a unique nozzle system, which should
lead to improved lung and reduced
oropharyngeal deposition vs other
types of inhaler [85,93]




[85] and higher lung de
patients with poor inhal
pMDI = pressurized metered dose inhaler; HFA = hydrofluoroalkane; DPI = dry powdarise regarding the differing loading techniques for indi-
vidual devices (e.g., self-contained reservoirs or blister
packs versus capsule insertion). Additionally, a higher in-
spiratory flow is required to operate this type of inhaler,
meaning that it may not be appropriate for patients
with very severe COPD [94,95]. The increased aerosol
production time provided by an SMI (1.5 seconds
compared to <0.5 seconds for most other inhalers)
may be an advantage for patients with low inspiratory
capacity or poor timing of inhalation to actuation, al-
though teaching and observing the patient’s technique
remains important [83].
Non-adherence is a well-documented issue in COPD
and is associated with detrimental effects on patient out-
comes [96,97]. Irrespective of the device type, a single de-
vice with once-daily dosing may provide a significant
advantage, potentially improving adherence and, therefore,
patient outcomes. Adherence is inversely related to the
number of medications patients take [96] and both treat-
ment persistence and adherence in patients with COPD
have been demonstrated to be lower in multiple long-
acting inhaler users, compared to single long-acting in-
haler users [98]. Additionally, a recent large retrospective
study reported that adherence was significantly higher in
those who initiated treatment with once-daily dosing ver-
sus more frequent dosing [82]. On the other hand, apart
from the possible advantage of once- over twice-dailyDisadvantages Combination
products
in development
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Table 6 Analysis of medical and prescription claims, May
2011-April 2012 [109]
Mean monthly patient volumea
Regimen Total COPD COPD only COPD + asthma
Tiotropium monotherapy 310,423 279,530 30,893
ICS/LABA 451,019 360,760 90,259
LABA + LAMA 5,888 5,479 410
Tiotropium + ICS/LABA 193,137 170,063 23,074
aData from IMS Health, LifeLink solutions, calculated from US CMS-1500
medical claims and NCPDP prescription claims during period May
2011-April 2012.
COPD = chronic obstructive pulmonary disease; ICS = inhaled corticosteroid;
LABA = long-acting β2-agonist; LAMA = long-acting muscarinic antagonist.
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tential advantage of greater improvement in night-time
airflow and symptoms, an issue that has recently been
reappraised [81].
Consideration of potential adverse effects of
LAMA/LABA combinations
The safety profiles of both LAMAs and LABAs are well
understood. However, when combining two entities, it is
important to understand both the similarities and differ-
ences in adverse events. Given that both muscarinic antag-
onists and β2-agonists can have a detrimental effect on the
cardiovascular system [26,99], these adverse events need
to be monitored carefully in development programs for
combination products. Initial results suggest that the
cardiovascular safety profile of glycopyrronium plus
indacaterol is similar to placebo, with no clinically signifi-
cant differences observed versus placebo [57,68], and, to
date, no safety concerns have been identified with
tiotropium plus olodaterol [51]. Free combinations of
LAMA/LABA also seem well tolerated. No differences in
blood pressure and pulse rate were observed with
tiotropium plus salmeterol versus single-agent therapies
[59] and the meta-analysis of tiotropium plus formoterol
data reported no differences in cumulative incidence of
adverse events for the combination (33.2%) versus
tiotropium alone (36.0%), stating that drug-related severe
adverse events and cardiac effects were relatively rare [74].
Emerging therapeutic approaches
Triple therapy
Triple therapy with LAMA plus LABA/ICS has also
been investigated, demonstrating benefits over mono-
therapy on lung function [48,100-102]. Additionally, a
pilot study of patients with advanced COPD reported
that triple therapy combined with pulmonary rehabilita-
tion provided a benefit in terms of lung function [103].
Some reports also suggest that triple therapy can provide
additional benefits, such as reduction in exacerbation
rate and mortality [104], although a recent systematic re-
view concluded that further, longer-term studies are re-
quired to determine the benefits of tiotropium plus
LABA and ICS [105], or the additional benefit of ICS on
top of LAMA/LABA combinations.
Dual muscarinic antagonist-β2-agonists (MABAs)
Another interesting concept is that of single molecules
with muscarinic antagonist-β2-agonist (MABA) activity.
While the prospect of combining muscarinic antagonism
and β2-agonism into one entity is highly attractive, this is a
new and challenging area of research [106]. The optimal
MABA should be designed to achieve balanced, high
potencies at both muscarinic and β2 receptors, for
consistency. The furthest developed MABA is GSK961081,which has demonstrated effective bronchoprotection
in vivo as proof of concept (NCT00478738) [106] and is
currently in Phase IIb studies. MABAs provide a fixed ratio
of muscarinic antagonist and β2-agonist activity at a cellu-
lar level, have a single pharmacokinetic profile, and deliver
a fixed ratio of muscarinic antagonist and β2-agonist to the
whole lung, simplifying both combination delivery device
and clinical development programs [4,5,107]. These prop-
erties suggest that MABAs have the potential to act as a
useful platform for triple therapy with an anti-inflammatory
agent.
Novel bronchodilators
A number of new bronchodilators with novel modes of
action are currently in early stages of development, in-
cluding K+ channel openers, Rho kinase inhibitors, and
analogs of vasoactive intestinal peptide; these have been
reviewed more extensively elsewhere [7]. Given the sub-
stantial evidence supporting a role of Rho kinase in
bronchoconstriction [108], Rho kinase inhibitors such as
Y-27632, Y-30141, Y-30694, and fasudil may currently
hold the most promise, demonstrating smooth muscle
relaxant properties in vitro [7]. Once further evidence of
efficacy and safety is available, these newer classes might
be used in combination with more conventional bron-
chodilators, leading to additional therapeutic options
and increased potential for individualized medication.
Conclusions
In summary, there is considerable evidence and guidance
to support use of the combination of a LAMA and a
LABA in COPD, a number of free LAMA and LABA
combinations have been studied, and several LABA/
LAMA FDCs are under development.
Although there is a clear rationale for the use of
LAMA and LABA combinations, a recent treatment
regimen analysis for patients with COPD (based on pre-
scription and medical claims) suggests that currently this
free combination is utilized much less frequently than
LAMA monotherapy (tiotropium), LABA/ICS
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LABA/ICS in clinical practice (Table 6). These data
show that regardless of the presence or absence of comor-
bid asthma, LABA/ICS is the most widely used of these
regimens, followed by tiotropium monotherapy. Interest-
ingly, triple therapy is already a substantially used thera-
peutic option (usage approximately 60% of that of
tiotropium monotherapy). LABA/ICS is more frequently
used in patients with comorbid asthma and COPD [109].
While this practice is to be expected, it is likely that the
perceived overlap between asthma and COPD is exagger-
ated due to the common misconception that a significant
bronchodilator response in patients with COPD implies
the coexistence of an asthmatic component.
The very limited clinical use of LAMA/LABA combin-
ation therapy indicated by these data is perhaps surprising,
given the current evidence base and GOLD guidance.
However, the evidence from ongoing programs will be
much more substantial and the future availability of
LAMA/LABA FDCs should make this therapeutic option
more convenient than separate administration by two in-
halers (typically with different dosing schedules), currently
the only option.
The rising number of both single-agent and combin-
ation therapies for COPD increases the number of treat-
ment options, and, hence, makes treatment choice more
complex. Further studies should be designed to provide
substantial evidence for future guideline recommenda-
tions. In particular, investigation into the optimal sequen-
cing of monotherapies and combination bronchodilators
would be of use to determine where LAMA/LABA FDC
therapy may be positioned in the treatment algorithm for
COPD. Furthermore, examination of the benefits of using
dual bronchodilation as initial maintenance therapy would
be of interest, along with which groups of patients may
benefit from this approach.
There is a growing appreciation of the benefits of
bronchodilation beyond lung function, such as exacerba-
tions [110], patient-reported outcomes, exercise toler-
ance [111] and exercise capacity, and daily activities
[16,112]. Trials of LABA/LAMA FDCs should assess
this wider range of outcomes in order to more fully
understand the broader benefits of increased broncho-
dilation on a patient’s life as a whole.
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